Point72 Asset Management L.P. Has $4.36 Million Stock Position in Silence Therapeutics plc (NASDAQ:SLN)

Point72 Asset Management L.P. increased its stake in shares of Silence Therapeutics plc (NASDAQ:SLN) by 35.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 633,100 shares of the company’s stock after purchasing an additional 165,300 shares during the period. Point72 Asset Management L.P. owned approximately 2.12% of Silence Therapeutics worth $4,356,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the stock. JPMorgan Chase & Co. bought a new position in shares of Silence Therapeutics during the 4th quarter valued at about $26,000. Barclays PLC increased its holdings in shares of Silence Therapeutics by 83.8% during the 4th quarter. Barclays PLC now owns 6,126 shares of the company’s stock worth $42,000 after acquiring an additional 2,793 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Silence Therapeutics during the 4th quarter worth approximately $69,000. Virtus ETF Advisers LLC increased its holdings in shares of Silence Therapeutics by 130.5% during the 4th quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company’s stock worth $74,000 after acquiring an additional 6,098 shares during the last quarter. Finally, Ameriprise Financial Inc. acquired a new position in shares of Silence Therapeutics during the 4th quarter worth approximately $113,000. 98.73% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Morgan Stanley decreased their price objective on Silence Therapeutics from $45.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, May 9th. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research note on Friday, March 7th. Chardan Capital dropped their target price on Silence Therapeutics from $55.00 to $35.00 and set a “buy” rating for the company in a research report on Friday, May 9th. The Goldman Sachs Group dropped their target price on Silence Therapeutics from $4.00 to $3.00 and set a “sell” rating for the company in a research report on Friday, May 9th. Finally, BMO Capital Markets lowered their price objective on Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating for the company in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Silence Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $33.83.

Silence Therapeutics Stock Performance

Shares of SLN stock opened at $4.96 on Tuesday. The company has a market cap of $148.45 million, a P/E ratio of -3.16 and a beta of 1.20. The stock has a 50 day simple moving average of $3.35 and a two-hundred day simple moving average of $5.84. Silence Therapeutics plc has a fifty-two week low of $1.97 and a fifty-two week high of $24.38.

Silence Therapeutics (NASDAQ:SLN) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.42). The firm had revenue of $0.14 million for the quarter, compared to the consensus estimate of $3.58 million. Silence Therapeutics had a negative net margin of 342.00% and a negative return on equity of 62.81%. On average, research analysts predict that Silence Therapeutics plc will post -1.77 earnings per share for the current year.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.